Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT ID: NCT07039110
Last Updated: 2026-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
700 participants
OBSERVATIONAL
2025-09-09
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.
Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
NCT03875508
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
NCT03875482
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
NCT04713592
High Dose Risankizumab for Psoriasis
NCT05283135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risankizumab
Participants will receive risankizumab as prescribed by their physician according to local label.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
* Decision to treat with risankizumab is made prior to and independently of study participation.
Exclusion Criteria
* Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
* Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
Edmonton, Alberta, Canada
Winnipeg Clinic /ID# 276751
Winnipeg, Manitoba, Canada
Wiseman Dermatology Research /ID# 276847
Winnipeg, Manitoba, Canada
Cca Medical Research /ID# 276944
Ajax, Ontario, Canada
Quinte dermatology /ID# 277497
Belleville, Ontario, Canada
Dermatrials Research /ID# 276714
Hamilton, Ontario, Canada
Lovegrove Dermatology /ID# 276797
London, Ontario, Canada
Lynderm Research Inc /ID# 276755
Markham, Ontario, Canada
Rejuvenation Dermatology Clinic Oakville /ID# 277492
Oakville, Ontario, Canada
JRB Research inc. /ID# 277730
Ottawa, Ontario, Canada
Factor Dermatology /ID# 278610
Ottawa, Ontario, Canada
SKiN Centre for Dermatology /ID# 277594
Peterborough, Ontario, Canada
Eternal Springtime Dermatology /ID# 278598
Thunder Bay, Ontario, Canada
North York Research Inc /ID# 276835
Toronto, Ontario, Canada
Toronto Dermatology Centre /ID# 276846
Toronto, Ontario, Canada
Centre for Medical and Surgical Dermatology /ID# 278775
Whitby, Ontario, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687
Saint-Jérôme, Quebec, Canada
Nemocnice Na Bulovce /ID# 275540
Prague, Central Bohemia, Czechia
Dermafit Centrum /ID# 275897
Pilsen, Plzeň Region, Czechia
Dermamedest /ID# 275898
Prague, Praha 2, Czechia
Nemocnice Ceske Budejovice /ID# 275541
České Budějovice, , Czechia
Centre Hospitalier de Niort Georges Renon /ID# 279604
Niort, Deux-Sevres, France
Dr. Rima Mohty /ID# 279951
Beauvais, Oise, France
Hôpitaux Drôme Nord - Romans /ID# 278109
Romans-sur-Isère, , France
Dr. med. Moritz Huber und Dr. med. Martin Heister /ID# 277627
Friedrichshafen, Baden-Wurttemberg, Germany
Dermakulm /Id# 277864
Kulmbach, Bavaria, Germany
Dermatologie Moelln Praxis Dr. Bodo Segert /ID# 277628
Mölln, Schleswig-Holstein, Germany
Private Practice - Dr. Mario Pawlak /ID# 277465
Heilbad Heiligenstadt, , Germany
Hautarztpraxis Dr. Med. Ulrike Wiemers / Dr. Med. Franca Wiemers /ID# 277821
Leipzig, , Germany
Hautarztpraxis Schwelm /ID# 277464
Schwelm, , Germany
University General Hospital Attikon /ID# 278389
Athens, Attica, Greece
General Hospital Andreas Syggros /ID# 276826
Athens, Attica, Greece
General Hospital Andreas Syggros /ID# 279246
Athens, Attica, Greece
Tzaneio Prefecture General Hospital of Piraeus /ID# 276532
Piraeus, Attica, Greece
Asklipieio General Hospital of Voula /ID# 278235
Voula, Attica, Greece
The University Hospital of Larissa /ID# 276576
Larissa, Larisa, Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 276488
Thessaloniki, , Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 276489
Thessaloniki, , Greece
Papageorgiou General Hospital /ID# 276487
Thessaloniki, , Greece
ASL 1 Abruzzo - Ospedale regionale San Salvatore /ID# 277341
L’Aquila, L Aquila, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 278080
Rome, Roma, Italy
Hokkaido University Hospital /ID# 278260
Sapporo, Hokkaido, Japan
Hosui General Medical Clinic /ID# 279520
Sapporo, Hokkaido, Japan
Kagoshima University Hospital /ID# 278514
Kagoshima, Kagoshima-ken, Japan
Yokohama City University Hospital /ID# 278257
Yokohama, Kanagawa, Japan
Kawasaki Medical School Hospital /ID# 278259
Kurashiki, Okayama-ken, Japan
Kindai University Hospital /ID# 278258
Sakai-shi, Osaka, Japan
Juntendo University Hospital /ID# 278495
Bunkyo-ku, Tokyo, Japan
Fukuoka University Hospital /ID# 278600
Fukuoka, , Japan
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 278434
Osaka, , Japan
Hospital General Universitario Santa María Del Rosell /ID# 277894
Cartagena, Murcia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P25-187
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.